Lyra Therapeutics (LYRA) Other Accumulated Expenses (2019 - 2025)
Quarterly Other Accumulated Expenses rose 9.05% to $518000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $518000.0 through Dec 2025, up 9.05% year-over-year, with the annual reading at $518000.0 for FY2025, 9.05% up from the prior year.
Lyra Therapeutics' Other Accumulated Expenses history spans 7 years, with the latest figure at $518000.0 for Q4 2025.
- Other Accumulated Expenses came in at $518000.0 for Q4 2025, up from $475000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $1.2 million in Q4 2023 to a low of $40000.0 in Q1 2022.
- The 5-year median for Other Accumulated Expenses is $299000.0 (2022), against an average of $384454.5.
- Year-over-year, Other Accumulated Expenses surged 324.83% in 2021 and then plummeted 61.41% in 2024.
- Lyra Therapeutics' Other Accumulated Expenses stood at $633000.0 in 2021, then grew by 4.11% to $659000.0 in 2022, then surged by 86.8% to $1.2 million in 2023, then tumbled by 61.41% to $475000.0 in 2024, then rose by 9.05% to $518000.0 in 2025.
- Per Business Quant, the three most recent readings for LYRA's Other Accumulated Expenses are $518000.0 (Q4 2025), $475000.0 (Q4 2024), and $1.2 million (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Lyra Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 518,000.00 |
| Dec 31, 2024 | 475,000.00 |
| Dec 31, 2023 | 1.23 Mn |
| Dec 31, 2022 | 659,000.00 |
| Sep 30, 2022 | 299,000.00 |
| Jun 30, 2022 | 115,000.00 |
| Mar 31, 2022 | 40,000.00 |
| Dec 31, 2021 | 633,000.00 |
| Sep 30, 2021 | 130,000.00 |
| Jun 30, 2021 | 66,000.00 |
| Mar 31, 2021 | 63,000.00 |
| Dec 31, 2020 | 149,000.00 |
| Sep 30, 2020 | 109,000.00 |
| Jun 30, 2020 | 109,000.00 |
| Mar 31, 2020 | 153,000.00 |
| Dec 31, 2019 | 110,000.00 |